1.1 	A bill for an act
1.2 	relating to insurance; requiring coverage for opioid analgesics with 
1.3 	abuse-deterrent properties;proposing coding for new law in Minnesota Statutes, 
1.4 	chapter 62Q.
1.5 	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.6 	Section 1. [62Q.528] OPIOID ANALGESICS WITH ABUSE-DETERRENT 
1.7 	PROPERTIES.
1.8 		Subdivision 1.Definitions. (a) For the purposes of this section, the following terms 
1.9 	have the meanings given them.
1.10 	(b) "Abuse-deterrent opioid analgesic drug product" means a brand or generic opioid 
1.11 	analgesic drug product approved by the United States Food and Drug Administration 
1.12 	(FDA) with abuse-deterrence labeling claims that indicate the drug product is expected to 
1.13 	result in a meaningful reduction in abuse of opioids.
1.14 	(c) "Opioid analgesic drug product" means a drug product in the opioid analgesic 
1.15 	drug class prescribed to treat moderate to severe pain or other conditions and includes 
1.16 	immediate release, extended release, and long-acting forms and whether or not combined 
1.17 	with other drug substances to form a single drug product or dosage form.
1.18 		Subd. 2.Required coverage. (a) A health plan that provides prescription drug 
1.19 	coverage must provide coverage for abuse-deterrent opioid analgesic drug products as a 
1.20 	preferred drug on the health plan company's drug formulary or preferred drug list.
1.21 	(b) Cost-sharing requirements for abuse-deterrent opioid analgesic drug products 
1.22 	must not exceed the lowest cost-sharing requirements applied to other covered prescription 
1.23 	drugs on the drug formulary or preferred drug list.
2.1 		Subd. 3.Prior authorization. (a) A health plan company shall not impose as part 
2.2 	of a prior authorization or utilization review requirement the use of a non-abuse-deterrent 
2.3 	opioid analgesic drug product in order to access an abuse-deterrent opioid analgesic drug 
2.4 	product.
2.5 	(b) Nothing in this subdivision prevents a health plan company from applying a 
2.6 	prior authorization requirement to an abuse-deterrent opioid analgesic drug product, so 
2.7 	long as the same prior authorization requirements are applied to non-abuse-deterrent 
2.8 	opioid analgesic drug products.

2.9 	EFFECTIVE DATE. This section is effective August 1, 2015, and applies to any 
2.10 	health plan issued or renewed on or after that date.